Spectral AI Q1 Revenue Plunges 40% to $3.99M, Swings to Net Loss
MDAI sits 81% above its 52-week low of $1.18.
Summary
Spectral AI, Inc. reported significantly weaker first-quarter 2026 financial results, with research and development revenue plummeting 40.5% year-over-year to $3.99 million. The company also swung to a net loss of $3.41 million, or ($0.11) per share, compared to a net income of $2.9 million and $0.11 EPS in the prior year. This sharp decline in performance comes despite the positive financial baseline established in the March 2026 10-K, which highlighted a $31.7 million BARDA funding advance and positive clinical trial results. The current report notes a quarter-over-quarter decline in BARDA reimbursements, which likely contributed to the revenue drop. For a company of this size, such a substantial deterioration in financial metrics is a material negative development that could pressure the stock. Investors will be watching for updates on BARDA funding, the progress of UK commercialization following UKCA approval, and the impact of the DeepView product launch on future revenue streams.
At the time of this announcement, MDAI was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.4M. The 52-week trading range was $1.18 to $3.21. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.